Quoin Pharmaceuticals Announces Further International Expansion of Ongoing Clinical Trials for Netherton Syndrome
Quoin Pharmaceuticals, Ltd. - American Depositary Shares (QNRX)
Company Research
Source: GlobeNewswire
Two Additional Clinical Sites to be Opened in the United Kingdom Both Sites are Recognized Centers of Excellence for Netherton Syndrome in the UK. Principal Investigator has Been Appointed and a Clinical Research Organization Has Been Engaged Additional Sites in other Western European Countries are being Finalized ASHBURN, Va., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, today announces the further expansion of its on-going Netherton Syndrome (NS) clinical studies to include two additional international sites in the United Kingdom (UK). These sites, Great Ormond Street Hospital and St. Thomas’ Hospital, both in London, are recognized centers of excellence for treating Netherton Syndrome patients in the UK. Both sites have available cohorts of patients potentially eligible to participate in Quoin’s studies. A Principal Investigator (PI
Show less
Read more
Impact Snapshot
Event Time:
QNRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
QNRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
QNRX alerts
High impacting Quoin Pharmaceuticals, Ltd. - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
QNRX
News
- Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2024 Financial ResultsGlobeNewswire
- Quoin Pharmaceuticals Initiates Clinical Testing of Lead Product in Pediatric Netherton Syndrome PatientGlobeNewswire
- Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024GlobeNewswire
- Quoin Pharmaceuticals announces insider share purchases [Seeking Alpha]Seeking Alpha
- Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COOGlobeNewswire
QNRX
Sec Filings
- 11/14/24 - Form SC
- 11/8/24 - Form 424B3
- 11/8/24 - Form 8-K
- QNRX's page on the SEC website